# Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

Study · id `cardio:ct-nct02458287` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02458287](<https://clinicaltrials.gov/study/NCT02458287>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02458287

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 299 participants.

## Technical summary

Registry record NCT02458287. Randomized; quadruple masking; primary purpose treatment. Start 2015-06 (actual); primary completion 2016-02 (actual). Results posted on 2017-12-19.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 299 participants (enrolled count; ClinicalTrials.gov record NCT02458287, source copy `cardio:ctgov-nct02458287-2017-12-19`, retrieved 2026-10-31)
- Started: 2015-06 (actual) (ClinicalTrials.gov record NCT02458287, source copy `cardio:ctgov-nct02458287-2017-12-19`, retrieved 2026-10-31)
- Primary completion: 2016-02 (actual) (ClinicalTrials.gov record NCT02458287, source copy `cardio:ctgov-nct02458287-2017-12-19`, retrieved 2026-10-31)
- Completion: 2016-02 (actual) (ClinicalTrials.gov record NCT02458287, source copy `cardio:ctgov-nct02458287-2017-12-19`, retrieved 2026-10-31)
- Results first posted: 2017-12-19 (ClinicalTrials.gov record NCT02458287, source copy `cardio:ctgov-nct02458287-2017-12-19`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT02458287, source copy `cardio:ctgov-nct02458287-2017-12-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02458287-2017-12-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
- Acronym: SPIRE-AI
- Condition: Hyperlipidemia
- Intervention (Biological): Bococizumab 150mg
- Intervention (Biological): Bococizumab 75mg
- Intervention (Biological): Bococizumab 150mg placebo
- Intervention (Biological): Bococizumab 75mg placebo
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: 07540e13ca2aff6c73545b0d70287a4de0775685cbd9718db2457fd0a7e66ee4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
